CF PharmTech, Inc. (H-share: 02652) filed its Monthly Return for Equity Issuer for the period ended 30 April 2026, confirming minor movements in issued share capital and continued compliance with Hong Kong’s public-float requirements.

Key details are as follows:

• Registered share capital remained unchanged at 411.98 million shares, comprising 302.22 million H-shares and 109.75 million domestic shares, each with a par value of RMB 1.

• During April, 0.16 million H-shares previously repurchased on 16 December 2025 were moved into treasury, reducing issued H-shares (excluding treasury shares) to 301.56 million. Correspondingly, treasury H-shares increased to 0.67 million. Total issued shares across all classes stayed constant at 302.22 million.

• No share options, warrants, convertibles or other equity-linked instruments were issued or exercised in the month.

• The company confirmed that the public float of its H-shares continues to meet the minimum threshold of 24.7 % set at listing.

The filing, submitted on 7 May 2026, was signed by Executive Director and Joint Company Secretary Zhu Yuyu.